Type 1 diabetes mellitus

Joslin's Diabetes Mellitus: Fourteenth Edition

Volumn , Issue , 2011, Pages 399-424

  Eisenbarth, George S ^a,b  

^a UNIVERSITY OF COLORADO DENVER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84971014181     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (357)

1. American Diabetes Association. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-1197.
2. Bellgrau D, Eisenbarth GS. Immunobiology of autoimmunity. In: Eisenbarth GS, ed. Endocrine and organ specific autoimmunity. Austin, TX: RG Landes, 1999:1-18.
3. Bach JF. Etiology and pathogenesis of human insulin-dependent diabetes mellitus. In: Volpe R, ed. Autoimmune endocrinopathies. Totowa, NJ: Humana Press, 1999:293-307.
4. Nepom GT, Kwok WW. Perspectives in diabetes: molecular basis for HLADQ associations with IDDM. Diabetes 1998;47:1177-1184.
5. Thorsby E. Invited anniversary review: HLA associated diseases. Hum Immunol 1997;53:1-11.
6. Mordes JP, Greiner DL, Rossini AA. Animal models of autoimmune diabetes mellitus. In: LeRoith D, Taylor SI, Olefsky JM, eds. Diabetes mellitus: a fundamental and clinical text. Philadelphia: Lippincott-Raven, 1996:349-360.
7. Foulis AK, Clark A. Pathology of the pancreas in diabetes mellitus. In: Kahn CR, Weir GC, eds. Joslin's diabetes mellitus, 13th ed. Philadelphia: Lea & Febiger, 1994:265-281.
8. Foulis AK, McGill M, Farquharson MA. Insulitis in type 1 (insulin-dependent) diabetes mellitus in man-macrophages, lymphocytes, and interferongamma containing cells. . Pathol 1991;165:97-103.
9. Noble JA, Valdes AM, Cook M, et al. The role of HLA class II genes in insulindependent diabetes mellitus: molecular analysis of 180 Caucasian, multiplex families. Am J Hum Genet 1996;59:1134-1148.
10. Todd JA. From genome to aetiology in a multifactorial disease, type 1 diabetes. Bioassays 1999;21:164-174.
11. Anonymous. Epidemiology of severe hypoglycemia in the diabetes control and complications trial. The DCCT Research Group. Am J Med 1991;90: 450-459.
12. Imagawa A, Hanafusa T, Miyagawa J. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. Osaka IDDM Study Group. . Engl J Med 2000;342:301-307.
13. Winter WE, Maclaren NK, Riley WJ, et al. Maturity-onset diabetes of youth in black Americans. . Engl J Med 1987;316:285-291.
14. Pinhas-Hamiel O, Dolan LM, Daniels SR, et al. Increased incidence of noninsulin-dependent diabetes mellitus among adolescents. . Pediatr 1996;128: 608-615.
15. Pinhas-Hamiel O, Dolan LM, Zeitler PS. Diabetic ketoacidosis among obese African-American adolescents with NIDDM. Diabetes Care 1997;20:484-486.
16. Rewers M, Bugawan TL, Norris JM, et al. Newborn screening for HLA markers associated with IDDM: diabetes autoimmunity study in the young (DAISY). Diabetologia 1996;39:807-812.
17. Schenker M, Hummel M, Ferber K, et al. Early expression and high prevalence of islet autoantibodies for DR3/4 heterozygous and DR4/4 homozygous offspring of parents with type I diabetes: the German BABYDIAB study. Diabetologia 1999;42:671-677.
18. Rosenbloom AL, Joe JR, Young RS, et al. Emerging epidemic of type 2 diabetes in youth. Diabetes Care 1999;22:345-354.
19. Aaltonen J, Björses P, Perheentupa J, et al. An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. Nat Genet 1997;17:399-403.
20. Verge CF, Stenger D, Bonifacio E, et al. Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibody) in type 1 diabetes: combinatorial islet autoantibody workshop. Diabetes 1998;47:1857-1866.
21. Redondo MJ, Eisenbarth GS. Autoimmune polyendocrine syndrome type II. In: Eisenbarth GS, ed. Endocrine and organ specific immunity. Austin, TX: RG Landes, 1999:41-61.
22. Pugliese A. Genetic protection from insulin-dependent diabetes mellitus. Diab Nutr Metab 1997;10(4):169-179.
23. Abiru N, Takino H, Yano M, et al. Clinical evaluation of non-insulin-dependent diabetes mellitus patients with autoantibodies to glutamic acid decarboxylase. . Autoimmun 1996;9:683-688.
24. Turner R, Stratton I, Horton V, et al. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. Lancet 1997; 350:1288-1293.
25. Balducci-Silano PL, Connor E, Maclaren NK. Association between insulindependent diabetes mellitus and other autoimmune diseases. In: LeRoith D, Taylor SI, Olefsky JM, eds. Diabetes mellitus: a fundamental and clinical text. Philadelphia: Lippincott-Raven, 1996:333-339.
26. Neufeld M, Maclaren NK, Blizzard RM. Two types of autoimmune Addison's disease associated with different polyglandular autoimmune (PGA) syndromes. Medicine (Baltimore) 1981;60:355-362.
27. Verge CF, Eisenbarth GS. Immunoendocrinopathy syndromes. In: Wilson JD, Foster DW, eds. Williams textbook of endocrinology. Philadelphia: WB Saunders, 1998:1651-1662.
28. Yu L, Brewer KW, Gates S, et al. DRB1*04 and DQ alleles: expression of 21-hydroxylase autoantibodies and risk of progression to Addison's disease. . Clin Endocrinol Metab 1999;84:328-335.
29. Bao F, Rewers M, Scott F, et al. Celiac disease. In: Eisenbarth GS, ed. Endocrine and organ specific autoimmunity. Austin, TX: RG Landes, 1999:85-96.
30. Bao F, Yu L, Babu S, et al. One third of HLA DQ2 homozygous patients with type 1 diabetes express celiac disease associated transglutaminase autoantibodies. . Autoimmun 1999;13:143-148.
31. Hoffenberg EJ, Bao F, Eisenbarth GS, et al. G.S. Silent celiac disease in American children at genetic risk. . Pediatr Gastroenterol Nutr 2000;31:S65(abstr).
32. Savilahti E, Ormala T, Saukkonen T, et al. Jejuna of patients with insulindependent diabetes mellitus (IDDM) show signs of immune activation. Clin Exp Immunol 1999;116:70-77.
33. Vitoria JC, Castano L, Rica I, et al. Association of insulin-dependent diabetes mellitus and celiac disease: a study based on serologic markers. . Pediatr Gastroenterol Nutr 1998;27:47-52.
34. Acerini CL, Ahmed ML, Ross KM, et al. Coeliac disease in children and adolescents with IDDM: Clinical characteristics and response to gluten-free diet. Diabet Med 1997;15:38-44.
35. Lorini R, Scotta MS, Cortona L, et al. Celiac disease and type I (insulindependent) diabetes mellitus in childhood: follow-up study. . Diabetes Complications 1996;10:154-159.
36. Saukkonen T, Savilahti E, Reijonen H, et al, and Childhood Diabetes in Finland Study Group. Coeliac disease: frequent occurrence after clinical onset of insulin-dependent diabetes mellitus. Diabet Med 1995;13:464-470.
37. Fernández-Castañer M, Molina A, López-Jimónez L, et al. Clinical presentation and early course of type 1 diabetes in patients with and without thyroid autoimmunity. Diabetes Care 1999;22:377-381.
38. Holl RW, Bohm B, Loos U, et al. Thyroid autoimmunity in children and adolescents with type 1 diabetes mellitus. Effect of age, gender and HLA type. Horm Res 1999;52:113-118.
39. Lorini R, d'Annunzio G, Vitali L, et al. IDDM and autoimmune thyroid disease in the pediatric age group. . Pediatr Endocrinol Metab 1996;9:89-94.
40. Gerstein HC. Incidence of postpartum thyroid dysfunction in patients with type I diabetes mellitus. Ann Intern Med 1993;118:419-423.
41. Davis RE, McCann VJ, Stanton KG. Type 1 diabetes and latent pernicious anaemia. Med J Aust 1992;156:160-162.
42. De Block CE, De Leeuw I, Van Gaal LF. High prevalence of manifestations of gastric autoimmunity in parietal cell antibody positive type 1 (insulin-dependent) diabetic patients: the Belgian Diabetes Registry. . Clin Endocrinol Metab 1999;84:4062-4067.
43. Snow CF. Laboratory diagnosis of vitamin B12 and folate deficiency: a guide for the primary care physician. Arch Intern Med 1999;159:1289-1298.
44. Eisenbarth GS, Gottlieb P. Immunoendocrinopathy syndromes. In: Larsen PR, Kronenberg H, Melmed S, et al. Williams textbook of endocrinology, 10th ed. Philadelphia: WB Saunders, 2003.
45. Betterle C, Volpato M, Pedini B, et al. Adrenal-cortex autoantibodies and steroid-producing cells autoantibodies in patients with Addison's disease: comparison of immunofluorescence and immunoprecipitation assays. . Clin Endocrinol Metab 1999;84:618-622.
46. Brewer KW, Parziale VS, Eisenbarth GS. Screening patients with insulindependent diabetes mellitus for adrenal insufficiency. . Engl J Med 1997;337: 202.
47. Furmaniak J, Sanders J, Rees Smith B. Autoantigens in the autoimmune endocrinopathies. In: Volpe R, ed. Autoimmune endocrinopathies. Totowa, NJ: Humana Press, 1999:183-216.
48. Not T, Horvath K, Hill ID, et al. Celiac disease risk in the USA: high prevalence of antiendomysium antibodies in healthy blood donors. Scand J Gastroenterol 1998;33:494-498.
49. Dietrich W, Ehnis T, Bauer M, et al. Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med 1997;3:797-801.
50. O'Connor TM, Cronin CC, Loane JF, et al. Type 1 diabetes mellitus, coeliac disease, and lymphoma: a report of four cases. Diabet Med 1999;16:614-617.
51. Arentz-Hansen H, Korner R, Molberg O, et al. The intestinal T cell response to alpha-gliadin in adult celiac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase. . Exp Med 2000;191:603-612.
52. van de Wal Y, Kooy YMC, van Veelen PA, et al. Small intestinal T cells of celiac disease patients recognize a natural pepsin fragment of gliadin. Proc Natl Acad Sci U S A 1998;95:10050-10054.
53. Sjöström H, Lundin KEA, Molberg O, et al. Identification of a gliadin T-cell epitope in coeliac disease: general importance of gliadin deamidation for intestinal T-cell recognition. Scand J Immunol 1998;48:111-115.
54. Hoffenberg EJ, Haas J, Drescher A, et al. A trial of oats in newly diagnosed celiac disease. . Pediatr 2000;137:361-366.
55. Holmes GKT, Prior P, Lane MR, et al. Malignancy in coeliac disease-effect of a gluten free diet. Gut 1989;30:333-338.
56. Perheentupa J, Miettinen A. Autoimmune polyendocrinopathy-candidiasisectodermal dystrophy. In: Eisenbarth GS, ed. Endocrine and organ specific autoimmunity. Austin, TX: RG Landes, 1999.
57. Scott HS, Heino M, Peterson P, et al. Common mutations in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy patients of different origins. Mol Endocrinol 1998;2:1112-1119.
58. Vaidya B, Imrie H, Geatch DR, et al. Association analysis of the cytotoxic T lymphocyte antigen-4 (CTLA-4) and autoimmune regulator-1 (AIRE-1) genes in sporadic autoimmune Addison's disease. . Clin Endocrinol Metab 2000;85:688-691.
59. Kemp EH, Ajjan RA, Husebye ES. A cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphism is associated with autoimmune Addison's disease in English patients. Clin Endocrinol 1998;49:609-613.
60. Heward JM, Allahabadia A, Armitage M, et al. The development of Graves' disease and the CTLA-4 gene on chromosome 2q33. . Clin Endocrinol Metab 1999;84:2398-2401.
61. van der Auwera BJ, Vandewalle CL, Schuit FC, et al. CTLA-4 gene polymorphism confers susceptibility to insulin-dependent diabetes mellitus (IDDM) independently from age and from other genetic or immune disease markers. The Belgian Diabetes Registry. Clin Exp Immunol 1997;10:98-103.
62. Gambelunghe G, Falorni A, Ghaderi M, et al. Microsatellite polymorphism of the MHC class I chain-related (MIC-A and MIC-B) genes marks the risk for autoimmune Addison's disease. . Clin Endocrinol Metab 1999;84:3701-3707.
63. Gambelunghe G, Ghaderi M, Cosentino A, et al. Association of MHC Class I chain-related A (MIC-A) gene polymorphism with type 1 diabetes. Diabetologia 2000;43:507-514.
64. Powell BR, Buist NR, Stenzel V. An X-linked syndrome of diarrhea, polyendocrinopathy, and fatal infection in infancy. . Pediatr 1982;100:731-737.
65. Bennett CL, Yoshioka R, Kiyosawa H, et al. X-Linked syndrome of polyendocrinopathy, immune dysfunction, and diarrhea maps to Xp11.23-Xq13.3. Am J Hum Genet 2000;66:461-468.
66. Ferguson PJ, Blanton SH, Saulsbury FT, et al. Manifestations and linkage analysis in X-linked autoimmunity-immunodeficiency syndrome. Am J Med Genet 2000;90:390-397.
67. Cilio CM, Bosco A, Moretti C, et al. Congenital autoimmune diabetes mellitus [Letter]. . Engl J Med 2000;342:1529-1531.
68. Bottazzo GF, Florin-Christensen A, Doniach D. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 1974;2: 1279-1283.
69. Eisenbarth GS. Type I diabetes mellitus. A chronic autoimmune disease. . Engl J Med 1986;314:1360-1368.
70. Redondo MJ, Yu L, Hawa M, et al. Late progression to type 1 diabetes of discordant twins of patients with type 1 diabetes: combined analysis of two twin series (United States and United Kingdom). Diabetes 1999;48:780(abst).
71. Johnston C, Millward BA, Hoskins P, et al. Islet-cell antibodies as predictors of the later development of type I (insulin-dependent) diabetes. Diabetologia 1989;32:382-386.
72. Redondo MJ, Rewers M, Yu L, et al. Genetic determination of islet cell autoimmunity in monozygotic twin, dizygotic twin, and non-twin siblings of patients with type 1 diabetes: prospective twin study. BMJ 1999;318:698-702.
73. Bingley PJ, Christie MR, Bonifacio E, et al. Combined analysis of autoantibodies improves prediction of IDDM in islet cell antibody-positive relatives. Diabetes 1994;43:1304-1310.
74. Verge CF, Gianani R, Kawasaki L, et al. Prediction of type I diabetes in firstdegree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes 1996;45:926-933.
75. Bingley PJ, Bonifacio E, Williams AJK, et al. Prediction of IDDM in the general population: strategies based on combinations of autoantibody markers. Diabetes 1997;46:1701-1710.
76. Wagner R, McNally JM, Bonifacio E, et al. Lack of immunohistological changes in the islets of nondiabetic, autoimmune, polyendocrine patients with D-selective GAD-specific islet cell antibodies. Diabetes 1994;43:851-856.
77. Srikanta S, Ganda OP, Jackson RA, et al. Type I diabetes mellitus in monozygotic twins: chronic progressive beta cell dysfunction. Ann Intern Med 1983; 99:320-326.
78. Srikanta S, Ganda OP, Rabizadeh A, et al. First-degree relatives of patients with type I diabetes mellitus. Islet cell antibodies and abnormal insulin secretion. . Engl J Med 1985;313:461-464.
79. Colman PG, McNair P, Steele C, et al. Linear decline in insulin production prior to development of type 1 diabetes-a reality. Diabetes 2000;49:A36(abst).
80. Gazda LS, Charlton B, Lafferty KJ. Diabetes results from a late change in the autoimmune response of NOD mice. . Autoimmun 1997;10:261-270.
81. Shimada A, Charlton B, Taylor-Edwards C, et al. D-cell destruction may be a late consequence of the autoimmune process in nonobese diabetic mice. Diabetes 1996;45:1063-1067.
82. McCulloch DK, Raghu PK, Johnston C, et al. Defects in beta-cell function and insulin sensitivity in normoglycemic streptozotocin-treated baboons: a model of preclinical insulin-dependent diabetes. . Clin Endocrinol Metab 1988; 67:785-792.
83. Sutherland DE, Sibley R, Xu XA, et al. Twin-to-twin pancreas transplantation: reversal and reenactment of the pathogenesis of type I diabetes. Trans Assoc Am Physicians 1984;97:80-87.
84. Foulis AK, Liddle CN, Farquharson MA, et al. The histopathology of the pancreas in type I diabetes (insulin dependent) mellitus: a 25-year review of deaths in patients under 20 years of age in the United Kingdom. Diabetologia 1986;29:267-274.
85. Eisenbarth GS. Genetic basis of autoimmune diabetes. In: Williams G, Habener JF, eds. Metabolic basis of common inherited diseases. Philadelphia: Harcourt Health Sciences/WB Saunders, 2003.
86. Hawkes CH. Twin studies in diabetes mellitus. Diabet Med 1997;17:347-352.
87. Petersen JS, Kyvik KO, Bingley PJ, et al. Population based study of prevalence of islet cell autoantibodies in monozygotic and dizygotic Danish twin pairs with insulin dependent diabetes mellitus. BMJ 1997;314:1575-1579.
88. Ikegami H, Ogihara T. Genetics of insulin-dependent diabetes mellitus. Endocrinol J 1996;43:605-613.
89. Kyvik KO, Green A, Beck-Nielsen H. Concordance rates of insulin dependent diabetes mellitus: a population based study of young Danish twins. BMJ 1995;311:913-917.
90. Fava D, Gardner S, Pyke D, et al. Evidence that the age at diagnosis of IDDM is genetically determined. Diabetes Care 1998;21:925-929.
91. Redondo MJ, Yu L, Hawa M, et al. Heterogeneity of type 1 diabetes: analysis of monozygotic twins in Great Britain and the United States. Diabetologia, 2001;44:354-362.
92. Hawa M, Rowe R, Lan MS, et al. Value of antibodies to islet protein tyrosine phosphatase-like molecule in predicting type 1 diabetes. Diabetes 1997;46: 1270-1275.
93. El-Hashimy M, Angelico MC, Martin BC, et al. Factors modifying the risk of IDDM in offspring of an IDDM parent. Diabetes 1995;44:295-299.
94. Rewers M, Ziegler A. Primary prevention of type 1 diabetes. Presented at the Fourth Congress of the Immunology of Diabetes Society, November 10-15, 1999.
95. Pugliese A. Unraveling the genetics of insulin-dependent type 1A diabetes: the search must go on. Diabetes Rev 1999;7:39-54.
96. Lernmark Å, Ott J. Sometimes it's hot, sometimes it's not. Nat Genet 1998;19: 213-214.
97. Pugliese A, Eisenbarth GS, Type 1 diabetes mellitus of man: genetic susceptibility and resistance. In: Eisenbarth GS, ed. Type 1 diabetes: molecular, cellular, and clinical immunology. New York: Oxford University Press, 1996:134-152.
98. Bodmer JG, Marsh SG, Albert ED, et al. Nomenclature for factors of the HLA system, 1996. Hum Immunol 1997;53:98-128.
99. Raum D, Awdeh Z, Yunis EJ, et al. Extended major histocompatibility complex haplotypes in type I diabetes mellitus. . Clin Invest 1996;4:449-454.
100. Valdes AM, Thomson G. Detecting disease-predisposing variants: the haplotype method. Am J Hum Genet 1997;60:703-716.
101. Price P, Witt C, Allcock R, et al. The genetic basis for the association of the 8.1 ancestral haplotype (A1,B8,DR3) with multiple immunopathological diseases. Immunol Rev 1999;167:257-274.
102. Lau HT, Yu M, Fontana A, et al. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 1996;273:109-112.
103. Dawkins RL, Martin E, Saueracker G, et al. Supratypes and ancestral haplotypes in IDDM: potential importance of central non-HLA MHC genes. . Autoimmun 1990;3:63-68.
104. Horton V, Stratton I, Bottazzo GF, et al. Genetic heterogeneity of autoimmune diabetes: age of presentation in adults is influenced by HLA DRB1 and DQB1 genotypes (UKPDS 43). UK Prospective Diabetes Study (UKPDS) Group. Diabetologia 1999;42:608-616.
105. Van der Auwera B, Van Waeyenberge C, Schuit F, et al, and Belgian Diabetes Registry. DRB1*0403 protects against IDDM in Caucasians with the high-risk heterozygous DQA1*0301-DQB1*0302/DQA1*501-DQB1*0201 genotype. Diabetes 1995;44:527-530.
106. Huang W, She J-X, Muir A, et al. High risk HLA-DR/DQ genotypes for IDD confer susceptibility to autoantibodies but DQB1*0602 does not prevent them. Autoimmun 1994;7:889-897.
107. Ronningen KS, Spurkland A, Iwe T, et al. Distribution of HLA-DRB1, -DQA1 and -DQB1 alleles and DQA1-DQB1 genotypes among Norwegian patients with insulin-dependent diabetes mellitus. Tissue Antigens 1991;37:105-111.
108. Baisch JM, Weeks T, Giles R, et al. Analysis of HLA-DQ genotypes and susceptibility in insulin-dependent diabetes mellitus. . Engl J Med 1990;22: 1836-1841.
109. Kockum I, Sanjeevi CB, Eastman S, et al. Population analysis of protection by HLA-DR and DQ genes from insulin-dependent diabetes mellitus in Swedish children with insulin-dependent diabetes and controls. Eur J Immunogenet 1995;22:443-465.
110. Tait BD, Mraz G, Harrison LC. Association of HLA-DQw3 (TA10-) with type 1 diabetes occurs with DR3/4 but not DR1/4 patients. Diabetes 1987;37: 926-929.
111. Awata T, Kuzuya T, Matsuda A, et al. Genetic analysis of HLA class II alleles and susceptibility to type I (insulin-dependent) diabetes mellitus in Japanese subjects. Diabetologia 1992;35:419-424.
112. Rich SS, Reusch J, Panter S, et al. Is there a genetic connection between IDDM and NIDDM? Diabetes 1986;35:95.
113. Park Y, Erlich H, Noble J, et al. Identical transmission pattern of HLA DRB1/DQB1 haplotypes to patients with type 1A diabetes among Koreans and Caucasians. Diabetes 1998;7:27A(abst).
114. Khalil I, D'Auriol L, Gobet M, et al. A combination of HLA-DQ beta Asp 57-negative and HLA-DQ alpha Arg 52 confers susceptibility to insulin-dependent diabetes mellitus. . Clin Invest 1990;85:1315-1319.
115. Kawasaki E, Noble J, Erlich H, et al. Transmission of DQ haplotypes to patients with type 1 diabetes. Diabetes 1998;47:1971-1973.
116. Lie BA, Ronningen KS, Akselsen HE, et al. Application and interpretation of transmission/disequilibrium tests: transmission of HLA-DQ haplotypes to unaffected siblings in 526 families with type 1 diabetes. Am J Hum Genet 2000; 66:740-743.
117. Undlien DE, Kockum I, Ronningen KS, et al. HLA associations in type 1 diabetes among patients not carrying high-risk DR3-DQ2 or DR4-DQ8 haplotypes. Tissue Antigens 1999;54:543-551.
118. Pugliese A, Kawasaki E, Zeller M, et al. Sequence analysis of the diabetesprotective human leukocyte antigen-DQB1*0602 allele in unaffected, islet cell antibody-positive first degree relatives and in rare patients with type 1 diabetes. . Clin Endocrinol Metab 1999;84:1722-1728.
119. Hattori M, Buse JB, Jackson RA, et al. The NOD mouse: recessive diabetogenic gene within the major histocompatibility complex. Science 1986;231: 733-735.
120. Acha-Orbea H, McDevitt HO. The first external domain of the nonobese diabetic mouse class II I-A chain is unique. Proc Natl Acad Sci U S A 1987;84: 2435-2439.
121. Redondo MJ, Kawasaki E, Mulgrew CL, et al. DR and DQ associated protection from type 1 diabetes: comparison of DRB1*1401 and DQA1*0102-DQB1*0602. Clin Endocrinol Metab 2000;85:3793-3797.
122. Greenbaum CJ, Cuthbertson D, Eisenbarth GS, et al. Islet cell antibody positive relatives with HLA-DQA1*0102, DQB1*0602: identification by the Diabetes Prevention Trial-1. . Clin Endocrinol Metab 2000;85:1255-1260.
123. Sheehy MJ, Scharf SJ, Rowe JR, et al. A diabetes-susceptible HLA haplotype is best defined by a combination of HLA-DR and -DQ alleles. . Clin Invest 1989;83:830-835.
124. Nakanishi K, Kobayashi T, Murase T, et al. Human leukocyte antigen-A24 and -DQA1*0301 in Japanese insulin-dependent diabetes mellitus: independent contributions to susceptibility to the disease and additive contributions to acceleration of beta-cell destruction. . Clin Endocrinol Metab 1999;84:3721-3725.
125. Noble JA, Valdes AM, Thomson G, et al. The HLA class II locus DPB1 can influence susceptibility to type 1 diabetes. Diabetes 2000;49:121-125.
126. Lie BA, Akselsen HE, Jones G, et al. HLA association in insulin-dependent diabetes mellitus: no independent association to particular DP genes. Hum Immunol 1997;55:170-175.
127. Bell GI, Horita S, Karam JH. A polymorphic locus near the human insulin gene is associated with insulin-dependent diabetes mellitus. Diabetes 1984;33: 176-183.
128. Bennett ST, Lucassen AM, Gough SCL, et al. Susceptibility to human type I diabetes at IDDM2 is determined by tandem repeat variation at the insulin gene minisatellite locus. Nat Genet 1995;9:284-292.
129. Bennett ST, Wilson AJ, Cucca F, et al. IDDM2-VNTR-encoded susceptibility to type 1 diabetes: dominant protection and parental transmission of alleles of the insulin gene-linked minisatellite locus. . Autoimmun 1996;9:415-421.
130. Vafiadis P, Bennett ST, Todd JA, et al. Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus. Nat Genet 1997;15: 289-292.
131. Pugliese A, Zeller M, Fernandez A, et al. The insulin gene is transcribed in the human thymus and transcription levels correlate with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type I diabetes. Nat Genet 1997;15:293-297.
132. Hanahan D. Peripheral-antigen-expressing cells in thymic medulla: factors in self-tolerance and autoimmunity. Curr Opin Immunol 1998;10:656-662.
133. Smith KM, Olson DC, Hirose R, et al. Pancreatic gene expression in rare cells of thymic medulla: evidence for functional contribution to T cell tolerance. Int Immunol 1997;9:1355-1365.
134. Leiter EH. Lessons from the animal models: the NOD mouse. In: Palmer JP, ed. Prediction, prevention, and genetic counseling in IDDM. Chichester, England: Wiley, 1996:201-227.
135. Atkinson MA, Leiter EH. The NOD mouse model of type 1 diabetes: as good as it gets? Nat Med 1999;5:601-604.
136. Wicker LS, Todd JA, Peterson LB. Genetic control of autoimmune diabetes in the NOD mouse. Annu Rev Immunol 1995;13:179-200.
137. Martin AM, Maxson MN, Leif J, et al. Diabetes-prone and diabetes-resistant BB rats share a common major diabetes susceptibility locus, iddm4: additional evidence for a "universal autoimmunity locus" on rat chromosome 4. Diabetes 1999;48:2138-2144.
138. Kawano K, Hirashima T, Moris S, et al. New inbred strain of Long-Evans Tokushima lean rats with IDDM without lymphopenia. Diabetes 1991;40: 1375-1381.
139. Verge CF, Vardi P, Babu S, et al. Evidence for oligogenic inheritance of type 1A diabetes in a large Bedouin Arab family. . Clin Invest 1998;102:1569-1575.
140. Larsen ZM, Kristiansen OP, Mato E, et al. IDDM12 (CTLA4) on 2q33 and IDDM13 on 2q34 in genetic susceptibility to type 1 diabetes (insulin-dependent). Autoimmunity 1999;31:35-42
141. Donner H, Rau H, Walfish PG, et al. CTLA4 alanine-17 confers genetic susceptibility to Graves' disease and to type-1 diabetes mellitus. . Clin Endocrinol Metab 1997;82:143-146.
142. Marron MP, Raffel LJ, Garchon HJ, et al. Insulin-dependent diabetes mellitus (IDDM) is associated with CTLA4 polymorphisms in multiple ethnic groups. Hum Mol Genet 1997;6:1275-1282.
143. Todd JA, Farrall M. Panning for gold: genome-wide scanning for linkage in type I diabetes. Hum Mol Genet 1996;5:1443-1448.
144. She J-X, Marron MP. Genetic susceptibility factors in type 1 diabetes: linkage disequilibrium and functional analyses. Curr Opin Immunol 1998;10:682-689.
145. Concannon P, Gogolin-Ewens KJ, Hinds DA, et al. A second-generation screen of the human genome for susceptibility to insulin-dependent diabetes mellitus. Nat Genet 1998;19:292-296.
146. Copeman JB, Cucca F, Hearne CM, et al. Linkage disequilibrium mapping of type 1 diabetes susceptibility gene (IDDM7) to chromosome 2q31-q33. Nat Genet 1995;9:80-85.
147. Luo D-F, Bui MM, Muir A, et al. Affected-sib-pair mapping of a novel susceptibility gene to insulin-dependent diabetes mellitus (IDDM8) on chromosome 6q25-q27. Am J Hum Genet 1995;57:911-919.
148. Field LL, Tobias R, Thomson G, et al. Susceptibility to insulin-dependent diabetes mellitus maps to a locus (IDDM11) on human chromosome 14q24.3-q31. Genomics 1996;33:1-8.
149. Morahan G, Huang D, Tait BD, et al. Markers on distal chromosome 2q linked to insulin-dependent diabetes mellitus. Science 1996;272:1811-1813.
150. Atkinson MA, Maclaren NK, Luchetta R. Insulitis and diabetes in NOD mice reduced by prophylactic insulin therapy. Diabetes 1990;39:933-937.
151. Daniel D, Wegmann DR. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). Proc Natl Acad Sci U S A 1996;93:956-960.
152. Hamman RF, Cook M, Keefer S, et al. Medical care patterns at the onset of insulin-dependent diabetes mellitus: association with severity and subsequent complications. Diabetes Care 1985;8:94-100.
153. Karjalajnen S, Salema P, IIonen J. A comparison of childhood and adult type 1 diabetes mellitus. . Engl J Med 1989;320:881-886.
154. Levy-Marchal C, Papoz L, de Beaufort C, et al. Clinical and laboratory features of type I diabetic children at time of diagnosis. Diabet Med 1992;9: 279-284.
155. Karvonen M, Tuomilehto J, Libman I, et al, and WHO DIAMOND Project Group. A review of the recent epidemiological data on the worldwide incidence of type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1993;36: 883-892.
156. Rewers M, Norris JM. Epidemiology of type I diabetes. In: Eisenbarth GS, Lafferty KJ, eds. Type I diabetes: molecular, cellular, and clinical immunology. New York: Oxford University Press, 1996:172-208.
157. Karvonen M, Pitkaniemi J, Tuomilehtov J. The onset age of type 1 diabetes in Finnish children has become younger. The Finnish Childhood Diabetes Registry Group. Diabetes Care 1999;22:1066-1070.
158. Muntoni S. New insights into the epidemiology of type 1 diabetes in Mediterranean countries. Diabetes Metab Res Rev 1999;15:133-140.
159. Dorman JS, McCarthy B, McCanlies E, et al, and the WHO DiaMond Molecular Epidemiology Sub-Project Group. Molecular IDDM epidemiology: international studies. Diabetes Res Clin Pract 1996;34:S17-S23.
160. Eisenbarth GS, Elsey C, Yu L, et al. Infantile anti-islet autoimmunity: DAISY study. Diabetes 1998;45[Suppl 1]:A219(abstr).
161. Ou D, Jonsen LA, Metzger DL, et al. CD4+ and CD8+ T-cell clones from congenital rubella syndrome patients with IDDM recognize overlapping GAD65 protein epitopes. Implications for HLA class I and II allelic linkage to disease susceptibility. Hum Immunol 1999;60:652-664.
162. Shaver KA, Boughman JA, Nance WE. Congenital rubella syndrome and diabetes: a review of epidemiologic, genetic, and immunologic factors. Am Ann Deaf 1985;130:526-532.
163. Ginsberg-Fellner F, Witt ME, Yagihashi S, et al. Congenital rubella syndrome as a model for type I (insulin-dependent) diabetes mellitus: increased prevalence of islet cell surface antibodies. Diabetologia 1984;27[Suppl]:87-89.
164. Rossini AA, Greiner DL, Friedman HP, et al. Immunopathogenesis of diabetes mellitus. Diabetes Rev 1993;1:43-75.
165. Jackson R, Rassi N, Crump A, et al. The BB diabetic rat. Profound T-cell lymphocytopenia. Diabetes 1981;30:887-889.
166. Jackson RA, Buse JB, Rifai R, et al. Two genes required for diabetes in BB rats. Evidence from cyclical intercrosses and backcrosses. . Exp Med 1984;159:1629-1636.
167. Markholst H, Eastman S, Wilson D, et al. Diabetes segregates as a single locus in crosses between inbred BB rats prone or resistant to diabetes. . Exp Med 1991;174:297-300.
168. Awata T, Guberski DL, Like AA. Genetics of the BB rat: association of autoimmune disorders (diabetes, insulitis, and thyroiditis) with lymphopenia and major histocompatibility complex class II. Endocrinology 1995;136: 5731-5735.
169. Jacob HJ, Pettersson A, Wilson D, et al. Genetic dissection of autoimmune type I diabetes in the BB rat. Nat Genet 1992;2:56-60.
170. Ellerman KE, Like AA. Susceptibility to diabetes is widely distributed in normal class IIu haplotype rats. Diabetologia 2000;43:890-898.
171. Daneman D, Fishman L, Clarson C, et al. Dietary triggers of insulin-dependent diabetes in the BB rat. Diabetes Res 1987;5:93-97.
172. Reddy S, Bibby NJ, Wu D, et al. A combined casein-free-nicotinamide diet prevents diabetes in the NOD mouse with minimum insulitis. Diabetes Res Clin Pract 1995;29:83-92.
173. Scott FW, Sarwar G, Cloutier HE. Diabetogenicity of various protein sources in the diet of the diabetes-prone BB rat. Adv Exp Med Biol 1988;246:277-285.
174. Helmke K, Otten A, Willems WR, et al. Islet cell antibodies and the development of diabetes mellitus in relation to mumps infection and mumps vaccination. Diabetologia 1986;29:30-33.
175. Bodansky HJ, Grant PJ, Dean BM, et al. Islet-cell antibodies and insulin autoantibodies in association with common viral infections. Lancet 1986;2: 1351-1353.
176. Champsaur H, Bottazzo GF, Bertrams J, et al. Virologic, immunologic and genetic factors in insulin-dependent diabetes mellitus. . Pediatr 1982;100: 15-20.
177. Uriarte A, Cabrera E, Ventura R, et al. Islet cell antibodies and ECHO-4 virus infection. Diabetologia 1987;30:590A(abst).
178. Rubinstein P, Walker ME, Fedun B, et al. The HLA system in congenital rubella patients with and without diabetes. Diabetes 1982;31:1088-1091.
179. Dahlquist G, Källón B. Early neonatal events and the disease incidence in nonobese diabetic mice. Pediatr Res 1997;42:489-491.
180. Hyöty H, Hiltunen M, Knip M, et al, and The Childhood Diabetes in Finland (DiMe) Study Group. Aprospective study of the role of coxsackie B and other enterovirus infections in the pathogenesis of IDDM. Diabetes 1995;44:652-657.
181. Clements GB, Galbraith DN, Taylor KW. Coxsackie B virus infection and onset of childhood diabetes. Lancet 1995;346:221-223.
182. Dahlquist GG, Ivarsson S, Lindberg B, et al. Maternal enteroviral infection during pregnancy as a risk factor for childhood IDDM. A population-based case-control study. Diabetes 1995;44:408-413.
183. Kaufman DL, Erlander MG, Clare-Salzler M, et al. Autoimmunity to two forms of glutamate decarboxylase in insulin-dependent diabetes mellitus. . Clin Invest 1992;89:283-292.
184. Graves PM, Rewers M. The role of enteroviral infections in the development of IDDM: limitations of current approaches. Diabetes 1997;46:161-168.
185. Oldstone MB, Nerenberg M, Southern P, et al. Virus infection triggers insulindependent diabetes mellitus in a transgenic model: role of anti-self (virus) immune response. Cell 1991;65:319-331.
186. Ohashi P, Oehen SH, Buerki K, et al. Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 1991;65: 305-317.
187. Rewers M, Atkinson M. The possible role of enteroviruses in diabetes mellitus. In: Rotbart HA, ed. Human enterovirus infections. Washington, DC: American Society for Microbiology, 1996:353-385.
188. Dahlquist G. Environmental risk factors in human type 1 diabetes-an epidemiological perspective. Diabetes Metab Rev 1998;11:37-46.
189. Graves PM, Barriga KJ, Norris JM, et al. Lack of association between early childhood immunizations and beta-cell autoimmunity. Diabetes Care 1999;22: 1694-1697.
190. Juhela S, Hyoty H, Roivainen M, et al. T-cell responses to enterovirus antigens in children with type 1 diabetes. Diabetes 2000;49:1308-1313.
191. Honeyman MC, Coulson BS, Stone NL, et al. Association between rotavirus infection and pancreatic islet autoimmunity in children at risk of developing type 1 diabetes. Diabetes 2000;49:1319-1324.
192. Allen HF, Klingensmith GJ, Jensen P, et al. Effect of BCG vaccination on newonset insulin-dependent diabetes mellitus: a randomized clinical study. Diabetes Care 1998;22:1703-1707.
193. Pozzilli P. BCG vaccine in insulin-dependent diabetes mellitus. IMDIAB Group. Lancet 1997;349:1520-1521.
194. Jefferson T. Real or perceived adverse effects of vaccines and the media-a tale of our times [Editorial]. . Epidemiol Community Health 2000;54:402-403.
195. Borch-Johnsen K, Joner G, Mandrup-Poulsen J, et al. Relation between breast-feeding and incidence rates of insulin-dependent diabetes mellitus. A hypothesis. Lancet 1984;2:1083-1086.
196. Martin JM, Trink B, Daneman D, et al. Milk proteins in the etiology of insulindependent diabetes mellitus (IDDM). Ann Med 1991;23:447-452.
197. Karjalainen J, Martin JM, Knip M, et al. Abovine albumin peptide as a possible trigger of insulin-dependent diabetes mellitus. . Engl J Med 1992;327:302-307.
198. Atkinson MA, Bowman MA, Kao K, et al. Lack of immune responsiveness to bovine serum albumin in insulin-dependent diabetes. . Engl J Med 1993;329: 1853-1858.
199. Glatthaar C, Whittall DE, Welborn TA, et al. Diabetes in Western Australian children: descriptive epidemiology. Med J Aust 1988;148:117-123.
200. Metcalfe MA, Baum JD. Family characteristics and insulin dependent diabetes. Arch Dis Child 1992;67:731-736.
201. Mayer ES, Hamman RF, Gay EC, et al. Reduced risk of IDDM among breastfed children: The Colorado IDDM Registry. Diabetes 1988;37:1625-1632.
202. Kostraba JN, Dorman JS, LaPorte RE, et al. Early infant diet and risk of IDDM in blacks and whites. A matched case-control study. Diabetes Care 1992;15: 626-631.
203. Kostraba JN, Cruickshanks KJ, Lawler-Heavner J, et al. Early exposure to cow's milk and solid foods in infancy, genetic predisposition and risk of IDDM. Diabetes 1993;42:288-295.
204. Patterson CC, Carson DJ, Hadden DR, et al. A case-control investigation of perinatal risk factors for childhood IDDM in Northern Ireland and Scotland. Diabetes Care 1994;17:376-381.
205. Blom L, Dahlquist G, Nystrom L, et al. The Swedish childhood diabetes study-social and perinatal determinants for diabetes in childhood. Diabetologia 1989;32:7-13.
206. Fort P, Lanes R, Dahlem S, et al. Breast feeding and insulin-dependent diabetes mellitus in children. . Am Coll Nutr 1986;5:439-441.
207. Siemiatycki J, Colle E, Campbell S, et al. Case-control study of IDDM. Diabetes Care 1989;12:209-216.
208. Kyvik KO, Green A, Svendsen A, et al. Breast feeding and the development of type 1 diabetes mellitus. Diabet Med 1991;9:233-235.
209. Bodington MJ, McNally PG, Burden AC. Cow's milk and type I childhood diabetes: no increase in risk. Diabet Med 1994;11:663-665.
210. Samuelsson U, Johansson C, Ludvigsson J. Breast-feeding seems to play a marginal role in the prevention of insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1993;19:203-210.
211. Soltesz G, Jeges S, Dahlquist G. Non-genetic risk determinants for type 1 (insulin-dependent) diabetes mellitus in childhood. Hungarian Childhood Diabetes Epidemiology Study Group. Acta Paediatr 1994;83:730-735.
212. Nigro G, Campea L, De Novellis A, et al. Breast-feeding and insulin-dependent diabetes mellitus [Letter]. Lancet 1985;1:467.
213. Virtanen SM, Rasanen L, Aro A, et al. Infant feeding in Finnish children less than 7 yr of age with newly diagnosed IDDM. Childhood Diabetes in Finland Study Group. Diabetes Care 1991;14:415-417.
214. Virtanen SM, Rasanen L, Aro A, et al. Feeding in infancy and the risk of type 1 diabetes mellitus in Finnish children. The Childhood Diabetes in Finland Study Group. Diabet Med 1992;9:815-819.
215. Verge CF, Howard NJ, Irwig L, et al. Environmental factors in childhood IDDM. Apopulation-based, case-control study. Diabetes Care 1994;17:1381-1389.
216. Gerstein HC. Cow's milk exposure and type I diabetes mellitus-a critical overview of the clinical literature. Diabetes Care 1994;17:13-19.
217. Vobecky JS, Vobecky J, Froda S. The reliability of the maternal memory in a retrospective assessment of nutritional status. . Clin Epidemiol 1988;41: 261-265.
218. Golding J, Haslum M. Breast-feeding and diabetes [Letter]. Med Sci Res 1987; 15:1135.
219. Norris JM, Beaty B, Klingensmith G, et al. Lack of association between early exposure to cow's milk protein and D-cell autoimmunity: Diabetes Autoimmunity Study in the Young (DAISY). JAMA 1996;276:609-614.
220. Akerblom HK, Savilahti E, Saukkonen TT, et al. The case for elimination of cow's milk in early infancy in the prevention of type 1 diabetes: the Finnish experience. Diabetes Metab Rev 1993;9:269-278.
221. Gerstein HC, Simpson JR, Atkinson S, et al. Feasibility and acceptability of a proposed infant feeding intervention trial for the prevention of type I diabetes. Diabetes Care 1995;18:940-942.
222. Martikainen A, Saukkonen T, Kulmala PK, et al. Disease-associated antibodies in offspring of mothers with IDDM. Diabetes 1996;45:1706-1710.
223. Schein PS, Alberti KG, Williamson DH. Effects of streptozotocin on carbohydrate and lipid metabolism in the rat. Endocrinology 1971;89:827-834.
224. Banerjee S. Effect of certain substances of the prevention of diabetogenic action of alloxan. Science 1947;128-130.
225. Pont A, Rubino JM, Bishop D, et al. Diabetes mellitus and neuropathy following Vacor ingestion in man. Arch Intern Med 1979;139:185-187.
226. Virtanen SM, Jaakkola L, Rasanen L, et al, and The Childhood Diabetes in Finland Study Group. Nitrate and nitrite intake and the risk for type I diabetes in Finnish children. Diabet Med 1994;11:656-662.
227. Kostraba JN, Gay EC, Rewers M, et al. Nitrate levels in community drinking waters and risk of IDDM. Diabetes Care 1992;15:1505-1508.
228. Dahlquist GG, Blom LG, Persson LA, et al. Dietary factors and the risk of developing insulin dependent diabetes in childhood. BMJ 1990;300: 1302-1306.
229. Elias D, Prigozin H, Polak N, et al. Autoimmune diabetes induced by the beta-cell toxin STZ. Immunity to the 60-kDa heat shock protein and to insulin. Diabetes 1994;43:992-998.
230. Toniolo A, Onodera T, Yoon JW, et al. Induction of diabetes by cumulative environmental insults from viruses and chemicals. Nature 1980;288:383-385.
231. Douek IF, Leech NJ, Gillmor HA, et al. Children with type-1 diabetes and their unaffected siblings have fewer symptoms of asthma. Lancet 1999;353: 1850.
232. Blom L, Nystrom L, Dahlquist G. The Swedish childhood diabetes study. Vaccinations and infections as risk determinants for diabetes in childhood. Diabetologia 1991;34:176-181.
233. Abiru N, Eisenbarth GS. Autoantibodies and autoantigens in type 1 diabetes: role in pathogenesis, prediction and prevention. Can J Diabetes Care 1999;23: 59-65.
234. Bonifacio E. Humoral immune markers: islet cell antibodies. In: Palmer JP, ed. Prediction, prevention, and genetic counseling in IDDM. Chichester, England: Wiley, 1996:43-62.
235. Christie MR. Humoral immune markers: antibodies to glutamic acid decarboxylase. In: Palmer JP, ed. Prediction, prevention, and genetic counseling in IDDM. Chichester, England: Wiley, 1996:77-96.
236. Gorsuch AN, Spencer KM, Lister J, et al. Can future type I diabetes be predicted? A study in families of affected children. Diabetes 1982;31:862-866.
237. Gorsuch AN, Spencer KM, Lister J, et al. Evidence for a long prediabetic period in type I (insulin-dependent) diabetes mellitus. Lancet 1981;2: 1363-1365.
238. Srikanta S, Ganda OP, Eisenbarth GS, et al. Islet cell antibodies and beta cell function in monozygotic triplets and twins initially discordant for type I diabetes mellitus. . Engl J Med 1983;308:322-325.
239. Dotta F, Gianani R, Previti M, et al. Autoimmunity to the GM2-1 islet ganglioside before and at the onset of type I diabetes. Diabetes 1996;45:1193-1196.
240. Yu L, Gianani R. GAD autoantibody levels in ICA positive relatives with restricted ICA. Diabetes 1993;42:65A(abst).
241. Seissler J, de Sonnaville JJ, Morgenthaler NG, et al. Immunological heterogeneity in type I diabetes: presence of distinct autoantibody patterns in patients with acute onset and slowly progressive disease. Diabetologia 1998;41:891-897.
242. Maclaren N, Lan M, Coutant R, et al. Only multiple autoantibodies to islet cells (ICA), insulin, GAD65, IA-2 and IA-2beta predict immune-mediated (type 1) diabetes in relatives. . Autoimmun 1999;12:279-287.
243. Verge CF, Gianani R, Kawasaki E, et al. Number of autoantibodies (against insulin, GAD or ICA512/IA2) rather than particular autoantibody specificities determines risk of type I diabetes. . Autoimmun 1996;9:379-383.
244. Bonifacio E, Genovese S, Braghi S, et al. Islet autoantibody markers in IDDM: risk assessment strategies yielding high sensitivity. Diabetologia 1995;38: 816-822.
245. Palmer JP, Asplin CM, Clemons P, et al. Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science 1983;222:1337-1339.
246. Castano L, Ziegler AG, Ziegler R, et al. Characterization of insulin autoantibodies in relatives of patients with type 1 diabetes. Diabetes 1993;42: 1202-1209.
247. Bohmer K, Keilacker H, Kuglin B, et al. Proinsulin autoantibodies are more closely associated with type 1 (insulin-dependent) diabetes mellitus than insulin autoantibodies. Diabetologia 1991;34:830-834.
248. Greenbaum C, Palmer JP, Kuglin B, et al, and Participating Laboratories. Insulin autoantibodies measured by radioimmunoassay methodology are more related to insulin-dependent diabetes mellitus than those measured by enzyme-linked immunosorbent assay: results of the Fourth International Workshop on the Standardization of Insulin Autoantibody Measurement. . Clin Endocrinol Metab 1992;74:1040-1044.
249. Williams AJK, Bingley PJ, Bonifacio E, et al. A novel micro-assay for insulin autoantibodies. . Autoimmun 1997;10:473-478.
250. Naserke HE, Dozio N, Ziegler A-G, et al. Comparison of a novel micro-assay for insulin autoantibodies with the conventional radiobinding assay. Diabetologia 1998;41:681-683.
251. Bilbao JR, Calvo B, Urrutia I, et al. Anti-insulin activity in normal newborn cord-blood serum: absence of IgG-mediated insulin binding. Diabetes 1997; 46:713-716.
252. Naserke HE, Bonifacio E, Ziegler A-G. Immunoglobulin G insulin autoantibodies in BABYDIAB offspring appear postnatally: sensitive early detection using a protein A/G-based radiobinding assay. . Clin Endocrinol Metab 1999; 84:1239-1243.
253. Yu L, Robles DT, Abiru N, et al. Early expression of anti-insulin autoantibodies of man and the NOD mouse: evidence for early determination of subsequent diabetes. Proc Natl Acad Sci U S A 2000;97:1701-1706.
254. Arslanian SL, Becker DJ, Rabin B, et al. Correlates of insulin antibodies in newly diagnosed children with insulin-dependent diabetes before insulin therapy. Diabetes 1985;34:926-930.
255. Vardi P, Ziegler AG, Matthews JH, et al. Concentration of insulin autoantibodies at onset of type I diabetes. Inverse log-linear correlation with age. Diabetes Care 1988;11:736-739.
256. Eisenbarth GS, Gianani R, Yu L, et al. Dual parameter model for prediction of type 1 diabetes mellitus. Proc Assoc Am Physicians 1998;110:126-135.
257. Bonifacio E, Scirpoli M, Kredel K, et al. Early autoantibody responses in prediabetes are IgG1 dominated and suggest antigen-specific regulation. . Immunol 1999;163:525-532.
258. Kimpimaki T, Kulmala P, Savola K, et al. Disease-associated autoantibodies as surrogate markers of type 1 diabetes in young children at increased genetic risk. Childhood Diabetes in Finland Study Group. . Clin Endocrinol Metab 2000;85:1126-1132.
259. Colman PG, McNair P, Margetts H, et al. The Melbourne Pre-Diabetes Study: prediction of type 1 diabetes mellitus using antibody and metabolic testing. Med J Aust 1998;169:81-84.
260. Baekkeskov S, Aanstoot H-J, Christgau S, et al. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase [published erratum appears in Nature 1990;347:782]. Nature 1990;347:151-156.
261. Solimena M, DeCamilli P. Autoimmunity to glutamic acid decarboxylase (GAD) in stiff-man syndrome and insulin-dependent diabetes mellitus. Trends Neurosci 1991;14:452-457.
262. Schwartz HL, Chandonia JM, Kash SF, et al. High-resolution autoreactive epitope mapping and structural modeling of the 65 kDa form of human glutamic acid decarboxylase. . Mol Biol 1999;287:983-999.
263. Rabin DU, Pleasic SM, Palmer-Crocker R, et al. Cloning and expression of IDDM-specific human autoantigens. Diabetes 1992;41:183-186.
264. Rabin DU, Pleasic SM, Shapiro JA, et al. Islet cell antigen 512 is a diabetesspecific islet autoantigen related to protein tyrosine phosphatases. . Immunol 1994;152:3183-3188.
265. Kawasaki E, Yu L, Gianani R, et al. Evaluation of islet cell antigen (ICA) 512/ IA-2 autoantibody radioassays using overlapping ICA512/IA-2 constructs. . Clin Endocrinol Metab 1997;82:375-380.
266. Lan MS, Lu J, Goto Y, Notkins AL. Molecular cloning and identification of a receptor-type protein tyrosine phosphatase, IA-2, from human insulinoma. DNA Cell Biol 1994;13:505-514.
267. Lu J, Li Q, Xie H, et al. Identification of a second transmembrane protein tyrosine phosphatase, IA-2 D, as an autoantigen in insulin-dependent diabetes mellitus: precursor of the 37-kDa tryptic fragment. Proc Natl Acad Sci U S A 1996;93:2307-2311.
268. Wasmeier C, Hutton JC. Molecular cloning of phogrin, a protein-tyrosine phosphatase homologue localized to insulin secretory granule membranes. . Biol Chem 1996;271:18161-18170.
269. Kawasaki E, Hutton JC, Eisenbarth GS. Molecular cloning and characterization of the human transmembrane protein tyrosine phosphatase homologue, phogrin, an autoantigen of type 1 diabetes. Biochem Biophys Res Commun 1996;227:440-447.
270. Christie MR, Vohra G, Champagne P, et al. Distinct antibody specificities to a 64-kD islet cell antigen in type 1 diabetes as revealed by trypsin treatment. . Exp Med 1990;172:789-794.
271. Payton MA, Hawkes CJ, Christie MR. Relationship of the 37,000-and 40,000-Mr tryptic fragments of islet antigens in insulin-dependent diabetes to the protein tyrosine phosphatase-like molecule IA-2 (ICA512). . Clin Invest 1995; 96:1506-1511.
272. Kawasaki E, Eisenbarth GS, Wasmeier C, et al. Autoantibodies to protein tyrosine phosphatase-like proteins in type I diabetes: overlapping specificities to phogrin and ICA512/IA-2. Diabetes 1996;45:1344-1349.
273. Kawasaki E, Yu L, Rewers MJ, et al. Definition of multiple ICA512/phogrin autoantibody epitopes and detection of intramolecular epitope spreading in relatives of patients with type 1 diabetes. Diabetes 1998;47:733-742.
274. Leslie RD, Atkinson MA, Notkins AL. Autoantigens IA-2 and GAD in type I (insulin-dependent) diabetes. Diabetologia 1999;42:3-14.
275. Medici F, Hawa MI, Giorgini A, et al. Antibodies to GAD65 and a tyrosine phosphatase-like molecule IA-2ic in Filipino type 1 diabetic patients. Diabetes Care 1999;22:1458-1461.
276. Naserke HE, Ziegler AG, Lampasona V, et al. Early development and spreading of autoantibodies to epitopes of IA-2 and their association with progression to type 1 diabetes. . Immunol 1998;161:6963-6969.
277. Savola K, Bonifacio E, Sabbah E, et al, and the Childhood Diabetes in Finland Study Group. IA-2 antibodies-a sensitive marker of IDDM with clinical onset in childhood and adolescence. Diabetologia 1998;41:424-429.
278. Gianani R, Rabin DU, Verge CF, et al. ICA512 autoantibody radioassay. Diabetes 1995;44:1340-1344.
279. Park Y, Kawasaki E, Yu L, et al. Humoral autoreactivity to an alternatively spliced variant of ICA512/IA2 in type 1 diabetes. Diabetologia 2000;43: 1293-1301.
280. Diez J, Zeller M, Park Y, et al. Differential splicing of the IA-2/ICA512 gene in pancreas and lymphoid organs as a permissive genetic mechanism for autoimmunity against the IA-1/ICA512 type 1 diabetes autoantigen. Diabetes 2001;50:895-900.
281. Yu L, Rewers M, Gianani R, et al. Anti-islet autoantibodies develop sequentially rather than simultaneously. . Clin Endocrinol Metab 1996;81:4264-4267.
282. Mennuni C, Santini C, Lazzaro D, et al. Identification of a novel type 1 diabetes-specific epitope by screening phage libraries with sera from pre-diabetic patients. . Mol Biol 1997;268:599-606.
283. Wong FS, Janeway CAJ. The role of CD4 vs. CD8 T cells in IDDM. . Autoimmun 1999;13:290-295.
284. Peterson JD, Haskins K. Transfer of diabetes in the NOD-scid mouse by CD4 T-cell clones. Differential requirement for CD8 T-cells. Diabetes 1996;45: 328-336.
285. Abiru N, Wegmann D, Kawasaki E, et al. Dual overlapping peptides recognized by insulin peptide B:9-23 reactive T cell receptor AV13S3 T cell clones of the NOD mouse. . Autoimmun 2000;14:231-237.
286. Wegmann DR, Norbury-Glaser M, Daniel D. Insulin-specific T cells are a predominant component of islet infiltrates in pre-diabetic NOD mice. Eur J Immunol 1994;24:1853-1857.
287. Anderson B, Park BJ, Verdaguer J, et al. Prevalent CD8+ T cell response against one peptide/MHC complex in autoimmune diabetes. Proc Natl Acad Sci U S A 1999;96:9311-9316.
288. Santamaria P, Utsugi T, Park B-J, et al. Beta-cell-cytotoxic CD8+ T cells from nonobese diabetic mice use highly homologous T cell receptor D-chain CDR3 sequences. . Immunol 1995;154:2494-2503.
289. DiLorenzo TP, Graser RT, Ono T, et al. Major histocompatibility complex class I-restricted T cells are required for all but the end stages of diabetes development in nonobese diabetic mice and use a prevalent T cell receptor alpha chain gene rearrangement. Proc Natl Acad Sci U S A 1998;95: 12538-12543. 289a. Lieberman SM, Evans AM, Han B, et al. Identification of the D'cell antigen targeted by a prevalent population of pathogenic CD8+ T cells in autoimmune diabetes. Proc Natl Acad Sci U S A 2003;100:8384-8388.
290. Roep BO, Stobbe I, Duinkerken G, et al. Auto-and alloimmune reactivity to human islet allografts transplanted into type 1 diabetic patients. Diabetes 1999;48:484-490.
291. Colman PG, Steele C, Couper JJ, et al. Islet autoimmunity in infants with a type I diabetic relative is common but is frequently restricted to one autoantibody. Diabetologia 2000;43:203-209.
292. Kulmala P, Savola K, Reijonen H, et al. Genetic markers, humoral autoimmunity, and prediction of type 1 diabetes in siblings of affected children. Childhood Diabetes in Finland Study Group. Diabetes 2000;49:48-58.
293. Ziegler A-G, Hummel M, Schenker M, et al. Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes. The 2-year analysis of the German BABYDIAB study. Diabetes 1999;48:460-468.
294. Yu J, Yu L, Bugawan TL, et al. Transient anti-islet autoantibodies: infrequent occurrence and lack of association with genetic risk factors. . Clin Endocrinol Metab 2000;85:2421-2428.
295. Tuomi T, Björses P, Falorni A, et al. Antibodies to glutamic acid decarboxylase and insulin-dependent diabetes in patients with autoimmune polyendocrine syndrome type I. . Clin Endocrinol Metab 1996;81:1488-1494.
296. Böhmer KP, Kolb H, Kuglin B, et al. Linear loss of insulin secretory capacity during the last six months preceding IDDM. Diabetes Care 1994;17:138-141.
297. Wagner R, Genovese S, Bosi E, et al. Slow metabolic deterioration towards diabetes in islet cell antibody positive patients with autoimmune polyendocrine disease. Diabetologia 1994;37:365-371.
298. Bleich D, Jackson RA, Soeldner JS, et al. Analysis of metabolic progression to type I diabetes in ICA+ relatives of patients with type I diabetes. Diabetes Care 1990;13:111-118.
299. Srikanta S, Ganda OP, Gleason RE, et al. Pre-type I diabetes. Linear loss of beta cell response to intravenous glucose. Diabetes 1984;33:717-720.
300. Bingley P. Interactions of age, islet cell antibodies, insulin autoantibodies, and first-phase insulin response in predicting risk of progression to IDDM in ICA+ relatives: the ICARUS data set. Diabetes 1996;45:1720-1728.
301. Carlsson A, Sundkvist G, Groop L, et al. Insulin and glucagon secretion in patients with slowly progressing autoimmune diabetes (LADA). . Clin Endocrinol Metab 2000;85:76-80.
302. Kobayashi T, Sugimoto T, Itoh T, et al. The prevalence of islet cell antibodies in Japanese insulin-dependent and non-insulin-dependent diabetic patients studies by indirect immunofluorescence and by a new method. Diabetes 1986;35:335-340.
303. Kobayashi T, Nakanishi K, Murase T, et al. Small doses of subcutaneous insulin as a strategy for preventing slowly progressive D-cell failure in islet cell antibody-positive patients with clinical features of NIDDM. Diabetes 1996;45:622-626.
304. Dorman JS, LaPorte RE, Kuller LH, et al. The Pittsburgh insulin-dependent diabetes mellitus (IDDM) morbidity and mortality study: mortality results. Diabetes 1984;33:271-276.
305. Scibilia J, Finegold D, Dorman J, et al. Why do children with diabetes die? Acta Endocrinol Suppl (Copenh) 1986;279:326-333. 305a. Barker JM, Goehrig SH, Barriga K, et al. Clinical characteristics of children diagnosed with type 1 diabetes through intensive screening and follow-up. Diabetes Care 2004;27:1399-1404.
306. Herskowitz-Dumont R, Wolfsdorf JI, Jackson RA, et al. Distinction between transient hyperglycemia and early insulin-dependent diabetes mellitus in childhood: a prospective study of incidence and prognostic factors. . Pediatr 1993;123:347-354.
307. Ricker AT, Herskowitz R, Wolfsdorf JI, et al. Prognostic factors in children and young adults presenting with transient hyperglycemia or impaired glucose tolerance. Diabetes 1986;35[Suppl 1]:93A(abst).
308. Füchtenbusch M, Ferber K, Standl E, et al. Prediction of type I diabetes postpartum in patients with gestational diabetes mellitus by combined islet cell autoantibody screening: a prospective multicenter study. Diabetes 1997;46: 1459-1467.
309. Kobberling J, Tillil H. Risk to family members of becoming diabetic: a study on the genetics of type I diabetes. Pediatr Adolesc Endocrinol 1986;15:26-38.
310. Krischer JP, Schatz DA, Silverstein JH, et al. Islet cell antibodies (ICA) predict the development of IDD in the school age general population as effectively as in unaffected relatives. Autoimmunity 1993;15[Suppl]:74(abst).
311. Bosi EP, Garancini MP, Poggiali F, et al. Low prevalence of islet autoimmunity in adult diabetes and low predictive value of islet autoantibodies in the general adult population of northern Italy. Diabetologia 1999;42:840-844.
312. Strebelow M, Schlosser M, Ziegler B, et al. Karlsburg type I diabetes risk study of a general population: frequencies and interactions of the four major type I diabetes-associated autoantibodies studied in 9419 schoolchildren. Diabetologia 1999;42:661-670.
313. Eisenbarth GS. Combinatorial autoantibody screening for prediction of type I diabetes. Clin Res 1993;41:154A(abst).
314. Pugliese A, Gianani R, Moromisato R, et al. HLA-DQB1*0602 is associated with dominant protection from diabetes even among islet cell antibody-positive first-degree relatives of patients with IDDM. Diabetes 1995;44:608-613.
315. Anonymous. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group. Ann Intern Med 1998;128:517-523. 315a. Palmer JP, Fleming GA, Greenbaum CJ, et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: Report of an ADA workshop, 21-22 October 2001. Diabetes 2004;53:250-264.
316. Hramiak IM, Dupre J, Finegood DT. Determinants of clinical remission in recent-onset IDDM. Diabetes Care 1993;16:125-132.
317. Martin S, Schernthaner G, Nerup J, et al. Follow-up of cyclosporin A treatment in type I (insulin-dependent) diabetes mellitus: lack of long-term effects. Diabetologia 1991;34:429-434.
318. Assan R, Feutren G, Debray-Sachs M, et al. Metabolic and immunological effects of cyclosporine in recently type I diabetes mellitus. Lancet 1985;1:67-71.
319. Carel J-C, Boitard C, Eisenbarth G, et al. Cyclosporine delays but does not prevent clinical onset in glucose intolerant pre-type 1 diabetic children. . Autoimmun 1996;9:739-745.
320. Harrison LC, Colman PG, Dean B, et al. Increase in remission rate in newly diagnosed type I diabetic subjects treated with azathioprine. Diabetes 1985; 34:1306-1308.
321. Silverstein J, Maclaren N, Riley W, et al. Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. . Engl J Med 1988;319:599-604.
322. Buckingham BA, Sandborg CI. A randomized trial of methotrexate in newly diagnosed patients with type 1 diabetes mellitus. Clin Immunol 2000;96:86-90.
323. Klingensmith G, Allen H, Hayward A, et al. Vaccination with BCG at diagnosis does not alter the course of IDDM. Diabetes 1997;46:193A(abst).
324. Chase HP, Butler-Simon N, Garg S, et al. A trial of nicotinamide in newly diagnosed patients with type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1990;33:444-446.
325. Pozzilli P, Visalli N, Ghirlanda G, et al. Nicotinamide increases C-peptide secretion in patients with recent onset type 1 diabetes. Diabet Med 1989;6: 568-572.
326. Elliott RB, Chase HP, Pilcher CC, et al. Effect of nicotinamide in preventing diabetes (IDDM) in children. . Autoimmun 1990;3:61A(abst).
327. Eisenbarth GS, Srikanta S, Jackson R, et al. Anti-thymocyte globulin and prednisone immunotherapy of recent onset type I diabetes mellitus. Diabetes Res 2:271-276.
328. Chaillous L, Lefevre H, Thivolet C, et al. Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Lancet 2000;356:545-549.
329. Pozzilli P, Pitocco D, Visalli N, et al. No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII). IMDIAB Group. Diabetologia 2000;43:1000-1004. 329a. Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. . Engl J Med 2002;346:1692-1698.
330. Herold KC, Bluestone JA, Montag AG, et al. Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody. Diabetes 1992;41: 385-391.
331. Chatenoud L, Primo J, Bach JF. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. . Immunol 1997;158:2947-2954.
332. Keller RJ, Jackson RA, Eisenbarth GS. Preservation of beta cell function in islet cell antibody (ICA) positive first degree relatives treated with insulin. Diabetes 1992;41[Suppl 1]:50A(abst).
333. Füchtenbusch M, Rabl W, Grassl B, et al. Delay of type 1 diabetes in high risk, first degree relatives by parenteral antigen administration: the Schwabing Insulin Prophylaxis Pilot Trial. Diabetologia 1998;41:536-541.
334. Lampeter EF, Klinghammer A, Scherbaum WA, et al. The Deutsche Nicotinamide Intervention Study: an attempt to prevent type 1 diabetes. DENIS Group. Diabetes 1998;47:980-984. 334a. Effects of insulin in relatives with type 1 diabetes mellitus. . Engl J Med 2002;346:1685-1691.
335. Lonnrot M, Korpela K, Knip M, et al. Enterovirus infection as a risk factor for beta-cell autoimmunity in a prospectively observed birth cohort: the Finnish Diabetes Prediction and Prevention Study. Diabetes 2000;49: 1314-1318.
336. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. . Engl J Med 2000;343:230-238.
337. Chatenoud L, Thervet E, Primo J, et al. Anti-CD3 antibody induces longterm remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci U S A 1994;91:123-127.
338. Wegmann DR, Eisenbarth GS. It's insulin. . Autoimmun 2000;15:286-291.
339. Ablamunits V, Elias D, Reshef T, et al. Islet T cells secreting IFN-gamma in NOD mouse diabetes: arrest by p277 peptide treatment. . Autoimmun 1998;11: 73-81.
340. Uchigata Y, Hirata Y. Insulin autoimmune syndrome (IAS, Hirata disease). In: Eisenbarth G, ed. Endocrine and organ specific autoimmunity. Austin, TX: RG Landes, 1999:133-148.
341. Hirata Y, Ishizu H, Ouchi N, et al. Insulin autoimmunity in a case with spontaneous hypoglycaemia. Jpn J Diabetes 1970;13:312-319.
342. Uchigata Y, Kuwata S, Tokunaga K, et al. Strong association of insulin autoimmune syndrome with HLA-DR4. Lancet 1992;339:393-394.
343. Hirata Y. Methimazole and insulin autoimmune syndrome with hypoglycemia. Lancet 1983;2:1037-1038.
344. Rodriguez O, Collier E, Arakaki R, et al. Characterization of purified autoantibodies to the insulin receptor from six patients with type B insulin resistance. Metabolism 1992;41:325-331.
345. Taylor SI, Barbetti F, Accili D, et al. Syndromes of autoimmunity and hypoglycemia. Autoantibodies directed against insulin and its receptor. Endocrinol Metab Clin North Am 1989;18:123-143.
346. Yamamoto T, Sato T, Mori T, et al. Clinical efficacy of insulin-like growth factor-1 in a patient with autoantibodies to insulin receptors: a case report. Diabetes Res Clin Pract 2000;49:65-69.
347. Lebovitz HE. Insulin allergy and insulin resistance. Curr Ther Endocrinol Metab 1997;6:500-504.
348. Schernthaner G. Immunogenicity and allergenic potential of animal and human insulins. Diabetes Care 1993;16:155-165.
349. Panczel P, Hosszufalusi N, Horvath MM. Advantage of insulin lispro in suspected insulin allergy. Allergy 2000;55:409-410.
350. Oh HK, Provenzano R, Hendrix J, et al. Insulin allergy resolution following pancreas transplantation alone. Clin Transplant 1998;12:593-595.
351. Gonzalo MA, De Argila D, Revenga F, et al. Cutaneous allergy to human (recombinant DNA) insulin. Allergy 1998;53:106-107.
352. Loeb JA, Herold KC, Barton KP, et al. Systematic approach to diagnosis and management of biphasic insulin allergy with local anti-inflammatory agents. Diabetes Care 1989;12:421-423.
353. Stegall MD, Lafferty KJ, Kam I, et al. Evidence of recurrent autoimmunity in human allogeneic islet transplantation. Transplantation 1996;61:1272-1274.
354. Boitard C, Bonifacio G, Bottazzo GF, et al. Immunology and Diabetes Workshop: report on the Third International (Stage 3) Workshop on the Standardisation of Cytoplasmic Islet Cell Antibodies. Held in New York, NY, October 1987. Diabetologia 1988;31:451-452.
355. Gianani R, Pugliese A, Bonner-Weir S, et al. Prognostically significant heterogeneity of cytoplasmic islet cell antibodies in relatives of patients with type I diabetes. Diabetes 1992;41:347-353.
356. Allen HF, Jeffers BW, Klingensmith GJ, et al. First-phase insulin release in normal children. . Pediatr 1993;123:733-738.
357. Vardi P, Crisa L, Jackson RA, et al. Predictive value of intravenous glucose tolerance test insulin secretion less than or greater than the first percentile in islet cell antibody positive relatives of type I (insulin-dependent) diabetic patients. Diabetologia 1991;34:93-102.